PIK3CA and breast carcinoma: Thus, we tested the response of 2 different HER2+PIK3CA-mutant breast cancer PDXs to paclitaxel and 4 different HER2-targeting agents (lapatinib, T-DM1, trastuzumab, and pertuzumab).